## 文章 8：打造個人化操作環境——WPS Office 介面與功能進階設定 WPS Office 雖然版面設計直覺，然而每個人使用習慣不同，若能依自己的需求進行微調，將能大幅提升效率。這篇文章將揭示幾個進階設定技巧，讓 WPS 更貼近使用者的心。 第一，設定文件標籤模式。WPS Office 預設啟用「多標籤式」文件切換，就如同瀏覽網頁一般，讓用戶在同一視窗快速點選不同文件。如果覺得這樣會占用頂端瀏覽空間，可在「設定」功能表中調整為「多視窗模式（彈出獨立視窗）」，方便雙螢幕用戶對照多份合約或數據專案。 第二，改變預設儲存格式與自動備份頻率。許多使用者發現 WPS 儲存文件預設為 .wps（個人）或特定格式，若經常與微軟 Office 用戶交換文件，可於進階設定中將「預設儲存」調整為 .docx 或 .pptx。同時，建議啟用「定時備份」功能，選取每 5 到 10 分鐘自動備份草稿。即使面臨停電或當機，也能將損失降到最低。 第三，整合個人化快捷鍵。若用戶習慣使用 Ctrl+S 的標準儲存快捷鍵，可延伸到自身常用的批次轉換或表格凍結功能。另外，在「功能定制」選項中關閉「線上資源推薦」和「特色功能推薦」，能大幅減少應用程式頂端的稻殼模組廣告。對於介面美學有要求的人，新版 WPS 內鍵數套色彩樣式與夜間模式，可在長時間工作時保護眼睛。 還有一個非常實用的客製化設定：調整預設字體。許多學術論文或公函需要指定的標題與內文字型（如 Times New Roman），透過修改預設樣式能確保每次開新文件直接套用，節省逐一設定的時間。使用者也可將常用的功能按鈕獨立拉出選單列。逐步調校之後，WPS Office 將不再是死板的軟體，而是拓展工作想像力的一扇窗戶。 Wps官网下载 ## 文章 8：打造個人化操作環境——WPS Office 介面與功能進階設定 WPS Office 雖然版面設計直覺，然而每個人使用習慣不同，若能依自己的需求進行微調，將能大幅提升效率。這篇文章將揭示幾個進階設定技巧，讓 WPS 更貼近使用者的心。 第一，設定文件標籤模式。WPS Office 預設啟用「多標籤式」文件切換，就如同瀏覽網頁一般，讓用戶在同一視窗快速點選不同文件。如果覺得這樣會占用頂端瀏覽空間，可在「設定」功能表中調整為「多視窗模式（彈出獨立視窗）」，方便雙螢幕用戶對照多份合約或數據專案。 第二，改變預設儲存格式與自動備份頻率。許多使用者發現 WPS 儲存文件預設為 .wps（個人）或特定格式，若經常與微軟 Office 用戶交換文件，可於進階設定中將「預設儲存」調整為 .docx 或 .pptx。同時，建議啟用「定時備份」功能，選取每 5 到 10 分鐘自動備份草稿。即使面臨停電或當機，也能將損失降到最低。 第三，整合個人化快捷鍵。若用戶習慣使用 Ctrl+S 的標準儲存快捷鍵，可延伸到自身常用的批次轉換或表格凍結功能。另外，在「功能定制」選項中關閉「線上資源推薦」和「特色功能推薦」，能大幅減少應用程式頂端的稻殼模組廣告。對於介面美學有要求的人，新版 WPS 內鍵數套色彩樣式與夜間模式，可在長時間工作時保護眼睛。 還有一個非常實用的客製化設定：調整預設字體。許多學術論文或公函需要指定的標題與內文字型（如 Times New Roman），透過修改預設樣式能確保每次開新文件直接套用，節省逐一設定的時間。使用者也可將常用的功能按鈕獨立拉出選單列。逐步調校之後，WPS Office 將不再是死板的軟體，而是拓展工作想像力的一扇窗戶。 Wps官网电脑版
Torsemide, a potent loop diuretic, has established itself as a cornerstone in the management of conditions characterized by fluid overload, most notably congestive heart failure (CHF), chronic kidney disease (CKD), and hepatic cirrhosis with ascites. Since its clinical introduction, it has offered a distinct pharmacological profile compared to its predecessor, furosemide, prompting extensive research into its efficacy, safety, and pharmacokinetic advantages. This article provides a comprehensive scientific review of torsemide, encompassing its mechanism of action, pharmacokinetics, clinical applications, and key considerations for therapeutic use. 1. Introduction and Chemical Profile Torsemide (1-isopropyl-3-[(4-m-toluidino-3-pyridyl) sulfonyl] urea) is a sulfonylurea class loop diuretic. It is a pyridine-sulfonylurea derivative, distinguishing it chemically from the sulfonamide-derived furosemide. This structural difference underpins several of its unique pharmacokinetic properties. As a loop diuretic, its primary site of action is the thick ascending limb of the loop of Henle in the nephron, where it potently inhibits electrolyte reabsorption. 2. Mechanism of Action The diuretic effect of torsemide is mediated through reversible inhibition of the Na+/K+/2Cl- cotransporter (NKCC2) in the luminal membrane of the thick ascending limb. By blocking this transporter, torsemide reduces the reabsorption of sodium, chloride, and potassium. This leads to a significant increase in the delivery of solutes to the distal tubule, resulting in profound diuresis and natriuresis. The subsequent reduction in plasma volume and preload is a critical therapeutic effect in heart failure. Furthermore, like other loop diuretics, torsemide induces venodilation shortly after intravenous administration, an effect believed to be mediated through prostaglandin release, which provides rapid preload reduction before the onset of diuresis. 3. Pharmacokinetics and Pharmacodynamics The pharmacokinetic profile of torsemide presents several potential advantages: Bioavailability: Torsemide exhibits high and reliable oral bioavailability (80-90%), which is less variable than that of furosemide (10-100%). This predictable absorption allows for more consistent dose-response relationships and facilitates easier transition between intravenous and oral administration. Metabolism and Excretion: Approximately 80% of torsemide is metabolized in the liver via the cytochrome P450 system (primarily CYP2C9, with minor roles for CYP2C8 and CYP2C19) into three main metabolites. The primary metabolite, M1, is pharmacologically active. Renal excretion accounts for about 20% of unchanged drug. This dual route of elimination (hepatic and renal) is advantageous in patients with renal impairment, as accumulation is less likely compared to diuretics solely reliant on renal excretion. Half-life and Duration: Torsemide has a longer elimination half-life (3-4 hours) compared to furosemide (1-1.5 hours), translating to a longer duration of action (6-8 hours). This permits once- or twice-daily dosing, potentially improving patient adherence and providing more sustained decongestion. Protein Binding: It is extensively bound to plasma proteins (>97%), which limits its filtration at the glomerulus and ensures targeted delivery to the secretory pathways in the proximal tubule for transport to its site of action in the loop of Henle. 4. Clinical Applications Congestive Heart Failure (CHF): Torsemide is a first-line agent for the management of edema associated with CHF. Its ability to reduce ventricular preload and afterload alleviates pulmonary and systemic congestion. Some studies, such as the TORIC and TORNADO trials, have suggested potential benefits beyond diuresis, including reduced hospitalizations for heart failure and possible positive effects on cardiac remodeling, Revisión Basada en Evidencia potentially linked to its anti-aldosteronic properties and reduced neurohormonal activation compared to furosemide. However, larger confirmatory trials are ongoing. Chronic Kidney Disease (CKD): Torsemide remains effective in patients with moderate to severe renal impairment due to its hepatic metabolism. It is often used to manage edema and hypertension in CKD patients. Hepatic Cirrhosis with Ascites: It is effective in managing ascites and edema in cirrhosis. Its use requires careful monitoring due to the risk of electrolyte disturbances and hepatorenal syndrome. It is often combined with aldosterone antagonists like spironolactone. Hypertension: While not a first-line antihypertensive, torsemide can be used for blood pressure control, particularly in patients with concomitant fluid overload or heart failure. Its longer duration may provide more sustained 24-hour blood pressure reduction. 5. Adverse Effects and Drug Interactions The adverse effect profile of torsemide is similar to other loop diuretics and is primarily related to its pharmacodynamic effects: Electrolyte and Metabolic Disturbances: Hypokalemia, hyponatremia, hypomagnesemia, and hypochloremic metabolic alkalosis are common. Regular monitoring and supplementation are essential. Ototoxicity: This risk is dose-dependent and more common with rapid intravenous administration and concurrent use of other ototoxic drugs (e.g., aminoglycosides). Renal Effects: Over-diuresis can lead to prerenal azotemia. It can also precipitate hyperuricemia and gout. Drug Interactions: NSAIDs can antagonize its diuretic and antihypertensive effects. Concurrent use with other antihypertensives can potentiate hypotension. It may enhance the nephrotoxicity of aminoglycosides and the ototoxicity of cisplatin. Due to its metabolism via CYP2C9, drugs that inhibit (e.g., amiodarone, fluconazole) or induce this enzyme can alter torsemide levels. 6. Therapeutic Considerations and Future Directions The choice between torsemide and furosemide involves consideration of pharmacokinetics, cost, and patient-specific factors. Torsemide’s predictable bioavailability and longer half-life may offer clinical benefits in terms of symptom control and adherence, potentially offsetting its typically higher acquisition cost. The ongoing TRANSFORM-HF trial (NCT03296813) is a large, pragmatic comparative effectiveness study directly comparing torsemide and furosemide on mortality and hospitalization in heart failure patients, which may provide definitive guidance. Emerging research continues to explore non-diuretic properties of torsemide, including its effects on myocardial fibrosis, aldosterone secretion, and sympathetic nervous system activity. These pleiotropic effects may contribute to its suggested benefits in cardiac remodeling. 7. Conclusion Torsemide is a potent and effective loop diuretic with a favorable pharmacokinetic profile characterized by high oral bioavailability, a longer duration of action, and dual hepatic/renal elimination. It plays a vital role in the management of edematous states across cardiology, nephrology, and hepatology. While its core mechanism is inhibition of the NKCC2 transporter, ongoing research investigates potential additional cardioprotective benefits. Clinical decision-making should be based on individual patient characteristics, therapeutic goals, and a careful assessment of risks, particularly electrolyte disturbances. As evidence evolves, particularly from large head-to-head trials, the precise positioning of torsemide within therapeutic algorithms for heart failure and other conditions will be further refined.
